Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Debt-to-Equity

: 0.00 (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

Bellicum Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Bellicum Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Bellicum Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-27.01 Mil. Bellicum Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bellicum Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 11 years, the highest Debt-to-Equity Ratio of Bellicum Pharmaceuticals was 36.23. The lowest was -5.04. And the median was 0.18.

BLCM's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Bellicum Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Bellicum Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.53

-1.45

-0.47

Bellicum Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellicum Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Debt-to-Equity falls into.

Bellicum Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bellicum Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	2.015
	=	0.00

Bellicum Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-27.014
	=	0.00

Bellicum Pharmaceuticals (OTCPK:BLCM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bellicum Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (OTCPK:BLCM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BPXA:Germany

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Executives

Charity Scripture	officer: Chief Development Officer	C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Stephen Davis	director	ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Charles S. Grass	officer: Principal Accounting Officer	C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Fair	director, officer: President and CEO	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
David Eric Strauss	officer: Director, Corporate Controller	2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Shane Ward	officer: Sr. VP and General Counsel	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Woodard Jr Joseph Paul	officer: SVP Clinical & Medical Affairs	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Aaron E. Foster	officer: Sr VP, Head of Research	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030
Rosemary Y. Williams	officer: Principal Accounting Officer	2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030
Judith V Klimovsky	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Atabak Mokari	officer: Sr. VP and CFO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Jon P Stonehouse	director	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
David M. Spencer	officer: Chief Scientific Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Alan A Musso	officer: CFO and Treasurer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139